Roche Receives the US FDA’s Approval for First CDx to Identify Endometrial Cancer Patients Eligible for Immunotherapy

Shots:

• The US FDA has approved Ventana MMR RxDx panel to identify endometrial cancer patients who are eligible for treatment with GSK’s Jemperli (monothx.) that has received the US FDA’s approval on Apr 22, 2021
• The CDx provides clinicians with a standardized testing option that uses a comprehensive panel of DNA mismatch repair (MMR) biomarkers tested by immunohistochemistry (IHC)
• Ventana MMR RxDx panel is the first immunohistochemistry predictive test that provides clinicians access to a fully automated, easy-to-use MMR test to identify patients who benefitted from Jemperli (dostarlimab-gxly)

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Spain’s News